Binding in Biological Technology

The Binding Site Announces Trading Update for Year Ended September 30th 2008

BIRMINGHAM, England, November 11 /PRNewswire/ -- - Revenues Expected to be up 26%, Freelite(TM) Sales up More Than 50% The Binding Site Limited ("The Binding Site" or the "Company"), a privately-owned specialist UK diagnostics company, today announces a trading update for the year ended 30...

Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation

TOKYO, and NEW DELHI, India, July 17 /PRNewswire/ -- Following intense speculation in sections of the media and the stock market, Daiichi Sankyo Company, Limited (TSE: 4568.JP) ("Daiichi Sankyo") and Ranbaxy Laboratories Limited (NSE/BSE: Ranbaxy/500359) ("Ranbaxy") reiterate that the agreemen...

Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests

Rosetta Genomics has Signed a Binding Term Sheet to Acquire Parkway Clinical Laboratories Inc., a Company Owning a Clinical Laboratory Improvement Act (CLIA) Certified Lab The Acquisition is Intended to Significantly Streamline the Development and Commercialization of Rose...

Awareness of Genzyme's Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected

EXTON, Pa., May 23 /PRNewswire/ -- BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Renvela report, the second in a multi-phase syndicated market research project tracking the launch of Renvela from baseline awareness through the first six months of product availability....

ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles

OXFORD, England, September 24 /PRNewswire/ -- ProImmune Ltd., a leading provider of quality research reagents for monitoring the immune system and services for antigen discovery, has announced the launch of its new MHC-peptide binding assay for Class II HLA alleles, adding to the series of dis...

Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets.

Vronique Brechler, David Handfield, Martin Boissonneault, Esther Tremblay, Benoit Houle and Luc Mnard. Introduction Recent advances in combinatorial chemistry and genomics programs have led to an unprecedented increase in both the number of compounds and potential...

Receptor Binding Assays using Fluorescence Polarization Detection: the [FP]2TM Characterized Tracers

A. Gagne, E. Robitaille, M. Harvey, J.-A. St. Pierre, D. Wenham and P. Banks Introduction High throughput screening is an indispensable tool for modern drug discovery 1-3 . The process is typically highly automated and can provide screening rates over 100,000 sample...

Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor

Sylviane Komesli, Martine Page, and Patrick Dutartre Dpartement dImmunologie, Laboratoires Fournier S.A., France Abstract TGF- type I and type II receptors form ligand dependent heteromeric signaling complexes, in which transforming growth fact...

Use of FlashPlate Technology for In Vitro Measurement of [35S]-GTPγS Binding in CHO Cells Expressing the Human 5-HT1B Receptor

J. Watson and J.V. Selkirk SmithKline Beecham Pharmaceuticals, UK Abstract FlashPlate is a 96-well white polystyrene microplate with scintillant-coated wells designed for highvolume, in-plate radiobinding assays. This study investigates the use...

Development of a CRF1 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System

Key words: CRF 1 • GPCR • receptor binding assay • LEADseeker • SPA Imaging Beads In the mammalian brain, the corticotrophin-releasing factor (CRF) system comprises four CRF-related peptides (CRF and urocortin 1, 2, and 3...

Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System

Key words: α 2c receptor • GPCR • receptor binding assay • LEADseeker • SPA Imaging Beads The α 2 -adrenergic receptors are G protein-coupled receptors that play a key role in the control of numerous physiol...

Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System

Key words: NK2 • GPCR • receptor binding assay • LEADseeker • SPA Imaging Beads Neurokinins, also known as tackykinins, are a family of small neuropeptides. Members of this family include peptides, substance P (SP), neurokin...

Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System

Key words: H 1 receptor • GPCR • receptor binding assay • LEADseeker • SPA Imaging Beads Histamine is a biogenic amine that plays important pathophysiological roles in central and peripheral tissues. Generally released from stimul...

The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System

Key words: Melanocortin • receptor binding assay • LEADseeker • SPA Imaging Beads Pro-melanocortins are present in high levels in the pituitary and are processed into three major peptide hormone fragments: adrenocorticotrophin (ACTH), th...

The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System

Key words: Melanocortin • receptor binding assay • LEADseeker • SPA Imaging Beads Pro-melanocortins are present in high levels in the pituitary and are processed into three major peptide hormone fragments: adrenocorticotrophin (ACTH), th...

Addition of imidazole during binding improves purity of histidine-tagged proteins

K. Hölscher, M. Richter-Roth, and B. Felden de Neumann GPC Biotech AG, Martinsried, Germany The purity of histidine-tagged proteins* purified by metal chelate affinity chromatography can often be improved by optimizing the imidazole concentration in the ...

Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia

...structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crys...

Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University

...ection and help combat drug resistance to HCV polymerase and protease inhibitors. We are rapidly advancing novel small molecule inhibitors of NS4B-RNA binding into the clinic for the benefit of clinicians and HCV patients." "The unique two component nature of the NS4B-RNA target appears to decrease th...

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

... against mutations conferring resistance to protease inhibitors, nucleoside polymerase inhibitors and non-nucleoside polymerase inhibitors that act at binding sites distinct from that of ANA598, and protease and nucleoside polymerase inhibitors retain full activity against mutations conferring resistance to ...

Sanofi-aventis Announces Second Quarter 2009 Results

...vel. This process generally lasts two-and-a-half to three months. On completion of the centralized procedure, the Commission issues a decision that is binding in all European Union countries. In some countries, additional time is required for pricing and reimbursement. Sanofi-aventis intends to defend its le...

Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech

... breast cancer. r84 is distinctive because it selectively blocks VEGF from binding to VEGF receptor 2 (VEGFR2), while non-selective agents such as Avastin block binding to both VEGFR2 and VEGF receptor 1 (VEGFR1). Selective anti-VEGF agents su...

Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government

...eceptor on cell surfaces and forms a protein-receptor complex that makes it possible for the anthrax toxins to enter the cells. Raxibacumab blocks the binding of protective antigen to cell surfaces and prevents the anthrax toxins from entering and killing the cells. About Human Genome Sciences ...

NYU physicists find way to explore microscopic systems through holographic video

...r radioactive. The holographic imaging technique, with its magnification and recording capabilities, allows researchers to observe molecular-scale binding without a tag, saving both time and money. Requiring just one microscopic bead to detect one type of molecule, holographic video microscopy promises ...

New method may accelerate drug discovery for difficult diseases like Parkinson's

...will be to determine precisely how the effective cyclic peptides affect Parkinson's disease cells by changing reduction or oxidation within the cell, binding to metal molecules, or perhaps another mechanism. In addition, more potent structures may be possible, so the cyclic peptides' known structure can be ...

Material world: Graphene's versatility promises new applications

... surface with antibodies, in order to precisely study their interaction with specific antigens. Such graphene-based biosensors could detect individual binding events, given a suitable sample. For other applications, adding impurities to graphene could raise overall interfacial capacitance. Ultracapacitors m...

Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax

...eceptor on cell surfaces and forms a protein-receptor complex that makes it possible for the anthrax toxins to enter the cells. Raxibacumab blocks the binding of protective antigen to cell surfaces and prevents the anthrax toxins from entering and killing the cells. About Human Genome Sciences T...

High-Tech 'Smart' Face Mask Helps Hong Kong Families Combat Swine Flu

...terminal sialic acid residue on the surface of the human cell membrane. The binding agent in the BioFriend(TM) textile mimics the binding action of sialic acid on influenza viruses. Typical face masks (incl...

Bioinformatics Expert Dr. Jiaan Yang Joins Sundia MediTech With Innovative PFSC Technology

...h R&D outsourcing company in Shanghai, China announced today that Sundia has acquired Protein Folding Shape Code (PFSC) technology for doing probe binding site for drug discovery from Microtech Nano LLC, a R&D Company in Indianapolis, IN, USA. As a part of this business deal, Dr. Jiaan Yang, the fou...

Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine

...tion and can be implemented in almost any radiation facility. Importantly, performance-related characteristics of the resulting drug product, such as binding potency and structural integrity, are maintained by the In-Line labeling process." "This new In-Line labeling process is elegant in its simplicit...

Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors

...structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crys...

Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates

...VT) platform to create New Chemical Entities (NCEs), by significantly improving already established drugs. The improvements are achieved by chemically binding specific unsaturated lipids to existing, and well understood, approved pharmaceuticals. Data generated suggests the resulting patentable NCEs offer im...

CEL-SCI Files Patent Application to Support Company's Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses

...f L.E.A.P.S. technology. Each L.E.A.P.S. construct is composed of a T cell binding ligand (TCBL) which has previously demonstrated the ability to induce and e...structs containing the antigenic disease epitope linked to an Immune/T-cell binding ligand (I/TCBL) can be manufactured by peptide synthesis or by covalently l...

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

... side effects observed with the marketed EGFR-targeted drugs result from their indiscriminant targeting of normal healthy tissues in addition to their binding to tumor." YM and its licensee Kuhnil Pharmaceutical Co. in Korea recently collaborated on a Phase I trial treating patients with palliative radioth...

ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet(R) RED384 and the Octet QK384

...re supported by Version 6 Octet software for data acquisition and analysis, which includes significant enhancements such as a 2:1 heterogeneous ligand binding model, data tracking and processing capabilities that assist in high-throughput screening. The new systems also include hardware and software robotic ...

BRAHMS, Cezanne and Lumiphore Announce Partnership for Diagnostic Tests

...hem to be used as extremely efficient time resolved fluorescence (TRF) reporters, and fluorescent resonance energy transfer (FRET) donors in proximity binding assays. These complexes have long emission lifetimes and offer a number of major advantages over existing fluorophores used for detection, including v...

Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours

... known to be involved in many types of cancer, could open the door to more effective oncology treatments in the future." "The disruption of the binding of the tumour promoter Raf-1 to the tumour suppressor Rb with Debio 0928 is a novel, first-in-class therapeutic strategy that has the potential for ta...

Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia

...VT) platform to create New Chemical Entities (NCEs), by significantly improving already established drugs. The improvements are achieved by chemically binding specific unsaturated lipids to existing, and well understood, approved pharmaceuticals. Data generated suggests the resulting patentable NCEs offer im...

Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight

...terminal sialic acid residue on the surface of the human cell membrane. The binding agent in the BioFriend(TM) textile mimics the binding action of sialic acid on influenza viruses. Typical face masks (incl...

Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation

...ce technologies. "The determination of ligand binding affinity has been used to delineate the ligand binding site of GPCRs through a site-directed mutagenesis ...d unique. It has aided the determination of ligand binding affinities without the use of radioactivity and wi...

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

...mune signaling, with recent research showing that exposed PS can have an immunosuppressive effect and dampen the body's normal response to cancer. By binding to and blocking PS, bavituximab is believed to boost the body's ability to combat cancer via this second immunostimulatory mechanism. Further informa...